Anzeige
+++Weltklasse Entdeckung von strategischen Metallen+++
DOVA PHARMACEUTI. DL-,001 WKN: A2DT59 ISIN: US25985T1025 Kürzel: 0AV Forum: Aktien Thema: Hauptdiskussion
Kommentare 7
Schorsch11,
01.10.2019 8:37 Uhr
0
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) announced it will be acquired by Swedish Orphan Biovitrum AB. Dova stockholders will be offered an upfront payment for $27.50 per share in cash, along with one non-tradeable Contingent Value Right (CVR) that entitles them to an additional $1.50 per share in cash upon regulatory approval of Doptelet for the treatment of chemotherapy-induced thrombocytopenia (CIT), representing a total potential consideration of up to $915m. Shares closed up 38% to $27.95.
Schorsch11,
27.06.2019 14:21 Uhr
0
DOVA PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION FOR DOPTELET® (AVATROMBOPAG) FOR TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)
http://investors.dova.com/news-releases/news-release-details/dova-pharmaceuticals-announces-fda-approval-supplemental-new
Schorsch11,
27.06.2019 9:43 Uhr
0
As of March 31, 2019, Dova had $92.7 million in cash and equivalents compared to $104.6 million as of December 31, 2018. Additionally, on May 6, 2019, Dova entered into an amended and restated loan agreement with Silicon Valley Bank that extends the interest only period of the existing $20 million loan facility by 12 months and provides additional potential borrowings of $30 million upon achieving certain clinical and revenue milestones.
https://finance.yahoo.com/news/dova-pharmaceuticals-reports-first-quarter-110000179.html?.tsrc=rss
Schorsch11,
27.06.2019 9:41 Uhr
0
sNDA under review by the U.S. FDA for DOPTELET for the treatment of chronic immune thrombocytopenia (ITP); PDUFA date June 30, 2019
Schorsch11,
25.06.2019 15:08 Uhr
0
Dova Pharmaceuticals Announces Four Presentations on Avatrombopag in Patients with Chronic Immune Thrombocytopenia at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress
https://finance.yahoo.com/news/dova-pharmaceuticals-announces-four-presentations-120000016.html?.tsrc=rss
Schorsch11,
25.06.2019 15:07 Uhr
0
Dova Pharmaceuticals Announces European Union Marketing Authorization for DOPTELET® (avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease
https://finance.yahoo.com/news/dova-pharmaceuticals-announces-european-union-120000914.html?.tsrc=rss
Meistdiskutiert
|
|
Thema | ||
|---|---|---|---|
| 1 | GAMESTOP Hauptdiskussion | -8,51 % | |
| 2 | NVIDIA Hauptdiskussion | +0,64 % | |
| 3 | Trading- und Aktien-Chat | ||
| 4 | Das neue Dax Prognose Forum | -0,35 % | |
| 5 | CYTOMX THERAPEUTICS INC. Hauptdiskussion | +1,53 % | |
| 6 | Vivoryon Therapeutics | +10,17 % | |
| 7 | PAG911 | -1,16 % | |
| 8 | Dax Prognose | -0,35 % | |
| 9 | EcoGraf Hauptdiskussion | +3,85 % | |
| 10 | PACIFIC BIOSCIENCES OF CALIFORNIA Hauptdiskussion | -2,44 % | Alle Diskussionen |
Anzeige
![Weltweit handeln ab 0 Euro - Zum Depot]()
Aktien
|
|
Thema | ||
|---|---|---|---|
| 1 | GAMESTOP Hauptdiskussion | -4,56 % | |
| 2 | NVIDIA Hauptdiskussion | +0,63 % | |
| 3 | CYTOMX THERAPEUTICS INC. Hauptdiskussion | +1,53 % | |
| 4 | Vivoryon Therapeutics | +10,17 % | |
| 5 | PAG911 | -0,97 % | |
| 6 | PACIFIC BIOSCIENCES OF CALIFORNIA Hauptdiskussion | -2,44 % | |
| 7 | Pineapple Energy | +10,03 % | |
| 8 | EcoGraf Hauptdiskussion | +3,85 % | |
| 9 | Der einzig Wahre Aixtron Stammtisch | +0,78 % | |
| 10 | Soll ich jetzt schon einsteigen? | +11,11 % | Alle Diskussionen |